Adolescent Initiation of Cannabis Use and Early-Onset Psychosis

Substance Abuse

Volumn 36, Issue 4, 2015, Pages 524-533

  Bagot, Kara S ^a   Milin, Robert ^b   Kaminer, Yifrah ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent; cannabis; early onset; psychosis

Indexed keywords

ADOLESCENT; ADOLESCENT BEHAVIOR; CANNABIS SMOKING; COMORBIDITY; HUMAN; ONSET AGE; PRODROMAL SYMPTOM; PSYCHOLOGY; PSYCHOSES, SUBSTANCE-INDUCED;

ADOLESCENT; ADOLESCENT BEHAVIOR; AGE OF ONSET; COMORBIDITY; HUMANS; MARIJUANA SMOKING; PRODROMAL SYMPTOMS; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 84947917122     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2014.995332     Document Type: Review

References (61)

1. Kaminer Y, Bukstein O., eds. Adolescent Substance Abuse: Psychiatric Comorbidity and High-Risk Behaviors. New York, NY: Routledge; 2008.
2. Hovens JG, Cantwell DP, Kiriakos R. Psychiatric comorbidity in hospitalized adolescent substance abusers. J Am Acad Child Adolesc Psychiatry. 1994; 33: 476-483.
3. Mazzoncini R, Donoghue K, Hart J, et al. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand. 2010; 121: 351-358.
4. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005; 112: 141-148.
5. Korkeila JA, Svirskis T, Heinimaa M, et al. Substance abuse and related diagnoses in early psychosis. Compr Psychiatry. 2005; 46: 447-452.
6. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry. 2006; 189: 229-234.
7. Sorbara F, Liraud F, Assens F, Abalan F, Verdoux H. Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. Eur Psychiatry. 2003; 18: 133-136.
8. Gururajan A, Manning EE, Klug M, van den Buuse M. Drugs of abuse and increased risk of psychosis development. Aust N Z J Psychiatry. 2012; 46: 1120-1135.
9. Schepis TS, Adinoff B, Rao U. Neurobiological processes in adolescent addictive disorders. Am J Addict. 2008; 17: 6-23.
10. Kleber HD, DuPont RL. Physicians and medical marijuana. Am J Psychiatry. 2012; 169: 564-568.
11. Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. Ann Emerg Med. 2014;63:684-689.
12. Wu LT, Brady KT, Mannelli P, Killeen TK. Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study. J Psychiatr Res. 2014; 50: 26-35.
13. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987; 2: 1483-1486.
14. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005; 31: 608-612.
15. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370: 319-328.
16. Ongur D, Lin L, Cohen BM. Clinical characteristics influencing age at onset in psychotic disorders. Compr Psychiatry. 2009; 50: 13-19.
17. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011; 68: 555-561.
18. Galvez-Buccollini JA, Proal AC, Tomaselli V, et al. Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res. 2012; 139: 157-160.
19. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002; 325: 1212-1213.
20. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004; 99: 1333-1341.
21. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003; 33: 15-21.
22. Cougnard A, Marcelis M, Myin-Germeys I, et al. Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis A psychosis proneness-persistence model. Psychol Med. 2007; 37: 513-527.
23. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011; 342: d738.
24. Schubart CD, van Gastel WA, Breetvelt EJ, et al. Cannabis use at a young age is associated with psychotic experiences. Psychol Med. 2011; 41: 1301-1310.
25. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev. 2000; 31: 371-384.
26. Ujike H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep. 2002; 4: 177-184.
27. Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association Drug Alcohol Depend. 2003; 69: 303-310.
28. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005; 57: 594-608.
29. Kumra S, Robinson P, Tambyraja R, et al. Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. J Am Acad Child Adolesc Psychiatry. 2012; 51: 171-180.
30. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005; 57: 1117-1127.
31. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004; 29: 1943-1961.
32. Lewis DA. Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology. 1997; 16: 385-398.
33. Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin Neurosci. 2013; 263: 3-13.
34. Rapp C, Bugra H, Riecher-Rossler A, Tamagni C, Borgwardt S. Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des. 2012; 18: 5070-5080.
35. Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry. 2008; 165: 490-496.
36. Johnston LD OMP, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 1975-2012. Ann Arbor: Institute for Social Research, The University of Michigan; 2013.
37. Baeza I, Graell M, Moreno D, et al. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res. 2009; 113: 129-137.
38. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010; 67: 440-447.
39. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006; 188: 237-242.
40. Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004; 66: 125-135.
41. Leeson VC, Harrison I, Ron MA, Barnes TR, Joyce EM. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull. 2012; 38: 873-880.
42. Schimmelmann BG, Conus P, Cotton S, Kupferschmid S, McGorry PD, Lambert M. Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry. 2012; 27: 463-469.
43. de la Serna E, Mayoral M, Baeza I, et al. Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers. J Nerv Ment Dis. 2010; 198: 159-162.
44. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005; 330: 11-25.
45. Compton MT, Broussard B, Ramsay CE, Stewart T. Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res. 2011; 126: 71-76.
46. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002; 325: 1199-1203.
47. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 30 2007; 151: 151-154.
48. Konings M, Henquet C, Maharajh HD, Hutchinson G, Van Os J. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatr Scand. 2008; 118: 209-213.
49. Miettunen J, Tormanen S, Murray GK, et al. Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br J Psychiatry. 2008; 192: 470-471.
50. Auther AM, McLaughlin D, Carrion RE, Nagachandran P, Correll CU, Cornblatt BA. Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. Psychol Med. 2012; 42: 2485-2497.
51. Yucel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. 2012; 38: 316-330.
52. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Res. 2005; 133: 35-43.
53. Wade D. Cannabis use and schizophrenia. Am J Psychiatry. 2005; 162: 401; author reply 402.
54. Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB. Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry. 2007; 20: 359-364.
55. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005; 20: 349-353.
56. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand. 2007; 115: 304-309.
57. Jacobus J, Bava S, Cohen-Zion M, Mahmood O, Tapert SF. Functional consequences of marijuana use in adolescents. Pharmacol Biochem Behav. 2009; 92: 559-565.
58. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res. 2005; 75: 135-137.
59. Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res. 2011; 128: 111-116.
60. Meyer RE. Psychobiology and the treatment of drug dependence: the biobehavioral interface. Am J Drug Alcohol Abuse. 1986; 12: 223-233.
61. Milin R, Walker S, Duffy A. Assessment and treatment of comorbid psychotic disorders and bipolar disorder. In: Kaminer Y, Winters K., ed. Clinical Manual of Adolescent Substance Abuse Treatment. Washington, DC: American Psychiatric Publishing, Inc.; 2011: 379-414.